RT Journal Article SR Electronic T1 Germline RUNX1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.04.29.21256340 DO 10.1101/2021.04.29.21256340 A1 Yizhen Li A1 Meenakshi Devidas A1 Wentao Yang A1 Stuart S. Winter A1 Wenjian Yang A1 Kimberly P. Dunsmore A1 Colton Smith A1 Maoxiang Qian A1 Xujie Zhao A1 Ranran Zhang A1 Julie M. Gastier-Foster A1 Elizabeth A. Raetz A1 William L. Carroll A1 Chunliang Li A1 Paul P. Liu A1 Karen R. Rabin A1 Takaomi Sanda A1 Charles G. Mullighan A1 Kim E. Nichols A1 William E. Evans A1 Ching-Hon Pui A1 Stephen P. Hunger A1 David T. Teachey A1 Mary V. Relling A1 Mignon L. Loh A1 Jun J. Yang YR 2021 UL http://medrxiv.org/content/early/2021/05/04/2021.04.29.21256340.abstract AB RUNX1 is a transcription factor critical for definitive hematopoiesis and genetic alterations in RUNX1 have been implicated in both benign and malignant blood disorders, particularly of the megakaryocyte and myeloid lineages. Somatic RUNX1 mutations are reported in B- and T-cell acute lymphoblastic leukemia (B-ALL and T-ALL), but germline genetic variation of RUNX1 in these lymphoid malignancies have not been comprehensively investigated. Sequencing 4,836 children with B-ALL and 1,354 cases of T-ALL, we identified 31 and 18 unique germline RUNX1 variants in these two ALL subtypes, respectively. RUNX1 variants in B-ALL were predicted to have minimal impact. By contrast, 54.5% of variants in T-ALL result in complete or partial loss of RUNX1 activity as a transcription activator in vitro, with dominant negative effects for 4 variants. Ectopic expression of dominant negative deleterious RUNX1 variants in human CD34+ cells repressed differentiation into erythroid, megakaryocytes, and T cells, while promoting differentiation towards myeloid cells. We then performed chromatin immunoprecipitation profiling in isogenic T-ALL models with variants introduced by genome editing of endogenous RUNX1. We observed highly distinctive patterns of DNA binding and target genomic loci by RUNX1 proteins encoded by the truncating vs missense variants. The p.G365R RUNX1 variant resulted in a novel methylation site in RUNX1 and alteration in its interaction with CBFβ. Further whole genome sequencing showed that JAK3 mutation was the most frequent somatic genomic abnormality in T-ALL with germline RUNX1 variants. Consistently, co-introduction of RUNX1 variant and JAK3 mutation in hematopoietic stem and progenitor cells in mouse gave rise to T-ALL with early T-cell precursor phenotype in vivo, compared to thymic T-ALL seen in mice with JAK3 mutation alone. Taken together, these results indicated that RUNX1 is an important predisposition gene for ALL, especially in T-ALL and also pointed to novel biology of RUNX1-mediated leukemogenesis in the lymphoid lineages.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialSt Jude Total studies: NCT00137111 AALL0434: NCT00408005 AALL0232: NCT00075725 AALL0331: NCT00103285 P9904: NCT00005585 P9905: NCT00005596 P9906: NCT00005603Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB was approved by the Institutional Review Board of St Jude Children's Research HospitalAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data in this manuscript are available.